GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » Price-to-Owner-Earnings

Winston Pharmaceuticals (Winston Pharmaceuticals) Price-to-Owner-Earnings : (As of Jun. 21, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-06-21), Winston Pharmaceuticals's share price is $0.0003. Winston Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Winston Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


WPHM's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.3
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-21), Winston Pharmaceuticals's share price is $0.0003. Winston Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2010 was $-0.03. Therefore, Winston Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-06-21), Winston Pharmaceuticals's share price is $0.0003. Winston Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.03. Therefore, Winston Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Winston Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Winston Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals Price-to-Owner-Earnings Chart

Winston Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Dec08 Dec09
Price-to-Owner-Earnings
- - - - -

Winston Pharmaceuticals Quarterly Data
Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Winston Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Winston Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Winston Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Winston Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Winston Pharmaceuticals's Price-to-Owner-Earnings falls into.



Winston Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Winston Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0003/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Winston Pharmaceuticals  (GREY:WPHM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Winston Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061
Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser 10 percent owner 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver director, officer: Vice President 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg director, officer: Chief Financial Officer 2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel 10 percent owner 4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines